My Size, Inc. Files 10-Q for Period Ending March 31, 2024
Ticker: MYSZ · Form: 10-Q · Filed: May 15, 2024 · CIK: 1211805
| Field | Detail |
|---|---|
| Company | My Size, INC. (MYSZ) |
| Form Type | 10-Q |
| Filed Date | May 15, 2024 |
| Risk Level | low |
| Pages | 15 |
| Reading Time | 18 min |
| Key Dollar Amounts | $0.001, $1 |
| Sentiment | neutral |
Sentiment: neutral
Topics: 10-Q, My Size, Inc., Quarterly Report, Financial Filing, SEC
TL;DR
<b>My Size, Inc. has submitted its quarterly report (10-Q) for the period ending March 31, 2024.</b>
AI Summary
My Size, Inc. (MYSZ) filed a Quarterly Report (10-Q) with the SEC on May 15, 2024. My Size, Inc. filed its 10-Q report for the quarterly period ended March 31, 2024. The filing covers the period from January 1, 2024, to March 31, 2024. The company's former names include Mysize Inc. and TOPSPIN MEDICAL INC. The company's principal business address is Hayarden 4, Airport City, L3, 7010000. The filing was made on May 15, 2024.
Why It Matters
For investors and stakeholders tracking My Size, Inc., this filing contains several important signals. This 10-Q filing provides investors with an update on the company's financial performance and operational status for the first quarter of 2024. Understanding the details within this report is crucial for assessing the company's current financial health and future prospects.
Risk Assessment
Risk Level: low — My Size, Inc. shows low risk based on this filing. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would alter the risk profile based solely on the header information.
Analyst Insight
Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand the company's performance and outlook.
Key Numbers
- 2024-03-31 — Period End Date (Conformed period of report)
- 2024-05-15 — Filing Date (Filed as of date)
- 2024-01-01 — Quarter Start Date (Reporting period)
- 2023-03-31 — Prior Year Quarter End (Comparison period)
Key Players & Entities
- My Size, Inc. (company) — Filer name
- MYSZ (company) — Ticker symbol
- 2024-03-31 (date) — Period of report
- 2024-05-15 (date) — Filing date
- Mysize Inc. (company) — Former company name
- TOPSPIN MEDICAL INC (company) — Former company name
- 7372 (industry_code) — Standard Industrial Classification
- DE (state) — State of incorporation
FAQ
When did My Size, Inc. file this 10-Q?
My Size, Inc. filed this Quarterly Report (10-Q) with the SEC on May 15, 2024.
What is a 10-Q filing?
A 10-Q is a quarterly financial report with unaudited financials, management discussion, and interim business updates. This particular 10-Q was filed by My Size, Inc. (MYSZ).
Where can I read the original 10-Q filing from My Size, Inc.?
You can access the original filing directly on the SEC's EDGAR system. The filing is publicly available and includes all exhibits and attachments submitted by My Size, Inc..
What are the key takeaways from My Size, Inc.'s 10-Q?
My Size, Inc. filed this 10-Q on May 15, 2024. Key takeaways: My Size, Inc. filed its 10-Q report for the quarterly period ended March 31, 2024.. The filing covers the period from January 1, 2024, to March 31, 2024.. The company's former names include Mysize Inc. and TOPSPIN MEDICAL INC..
Is My Size, Inc. a risky investment based on this filing?
Based on this 10-Q, My Size, Inc. presents a relatively low-risk profile. The filing is a standard quarterly report (10-Q) and does not contain immediate, significant financial or operational disclosures that would alter the risk profile based solely on the header information.
What should investors do after reading My Size, Inc.'s 10-Q?
Review the detailed financial statements and management's discussion and analysis within the 10-Q to understand the company's performance and outlook. The overall sentiment from this filing is neutral.
How does My Size, Inc. compare to its industry peers?
My Size, Inc. operates in the software services industry, specifically prepackaged software (SIC 7372).
Are there regulatory concerns for My Size, Inc.?
The company is subject to SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) under the Securities Exchange Act of 1934.
Industry Context
My Size, Inc. operates in the software services industry, specifically prepackaged software (SIC 7372).
Regulatory Implications
The company is subject to SEC regulations for public companies, including the requirement to file quarterly reports (10-Q) under the Securities Exchange Act of 1934.
What Investors Should Do
- Analyze the financial statements for revenue, expenses, and profitability for Q1 2024.
- Review the Management's Discussion and Analysis (MD&A) section for insights into business operations and future outlook.
- Check for any significant disclosures regarding risks, legal proceedings, or subsequent events.
Key Dates
- 2024-03-31: Quarterly Period End — End of the reporting period for the 10-Q filing.
- 2024-05-15: Filing Date — Date the 10-Q report was officially filed with the SEC.
Year-Over-Year Comparison
This is the 10-Q filing for the first quarter of 2024, providing updated financial information compared to the previous quarter's filings and the annual report.
Filing Stats: 4,610 words · 18 min read · ~15 pages · Grade level 14.3 · Accepted 2024-05-15 16:29:36
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share MYSZ Nasdaq Ca
- $1 — 3 (*) Represents an amount less than $1. (**) Adjusted to give retroactive e
Filing Documents
- form10-q.htm (10-Q) — 910KB
- ex31-1.htm (EX-31.1) — 19KB
- ex31-2.htm (EX-31.2) — 19KB
- ex32-1.htm (EX-32.1) — 6KB
- ex32-2.htm (EX-32.2) — 6KB
- 0001493152-24-019910.txt ( ) — 4025KB
- mysz-20240331.xsd (EX-101.SCH) — 27KB
- mysz-20240331_cal.xml (EX-101.CAL) — 46KB
- mysz-20240331_def.xml (EX-101.DEF) — 92KB
- mysz-20240331_lab.xml (EX-101.LAB) — 260KB
- mysz-20240331_pre.xml (EX-101.PRE) — 203KB
- form10-q_htm.xml (XML) — 538KB
- FINANCIAL INFORMATION
PART I - FINANCIAL INFORMATION 1 Item 1. Condensed Consolidated Interim Financial Statements (Unaudited) 2 Condensed Consolidated Interim Balance Sheets 3 Condensed Consolidated Interim Statements of Comprehensive Loss 4 Condensed Consolidated Interim Statements of Changes in Stockholders' Equity 5 Condensed Consolidated Interim Statements of Cash Flows 7 Notes to Condensed Consolidated Interim Financial Statements 8 Item 2. Management's Discussion & Analysis of Financial Condition and Results of Operations 16 Item 3. Quantitative and Qualitative Disclosure About Market Risk 21 Item 4.
Controls and Procedures
Controls and Procedures 21
- OTHER INFORMATION
PART II - OTHER INFORMATION 22 Item 1.
Legal Proceedings
Legal Proceedings 22 Item 1A.
Risk Factors
Risk Factors 22 Item 2. Unregistered Sales of Equity Securities and Use of Proceeds 24 Item 3. Defaults Upon Senior Securities 24 Item 4. Mine Safety Disclosures 24 Item 5 Other information 24 Item 6. Exhibits 24 i PART I FINANCIAL INFORMATION Item 1. Financial Statements. My Size, Inc. and Subsidiaries Condensed Consolidated Interim Financial As of March 31, 2024 (unaudited) U.S. Dollars in Thousands 1 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Financial Statements as of March 31, 2024 (Unaudited) Contents Page Condensed Consolidated Interim Balance Sheets (Unaudited) 3 Condensed Consolidated Interim Statements of Comprehensive Loss (Unaudited) 4 Condensed Consolidated Interim Statements of Changes in Stockholders' Equity (Unaudited) 5-6 Condensed Consolidated Interim Statements of Cash flows (Unaudited) 7 Notes to Condensed Consolidated Interim Financial Statements (Unaudited) 8-15 2 MY SIZE, INC. AND ITS SUBSIDIARIES Condensed Consolidated Interim Balance Sheets (Unaudited) U.S. dollars in thousands (except share data and per share data) March 31, December 31, 2024 2023 Assets Current Assets: Cash and cash equivalents 1,136 2,187 Restricted cash 75 77 Short term deposit - 22 Inventory 2,136 2,879 Account receivables 406 615 Other receivables and prepaid expenses 1,001 847 Total current assets 4,754 6,627 Long term deposits 7 7 Property and equipment, net 113 121 Operating right-of-use asset 48 351 Intangible assets 996 1,097 Goodwill 741 758 Investment in JV - 24 Investment in marketable securities 11 6 Total non-current assets 1,916 2,364 Total assets 6,670 8,991 Liabilities and stockholders' equity Current liabilities: Operating lease liability 53 158 Bank overdraft and short-term loans 582 158 Trade payables 1,114 2,154 Liabilities to Related parties 73 605
financial statements and the notes thereto for the year ended December 31, 2023
financial statements and the notes thereto for the year ended December 31, 2023. b. Significant Accounting Policies: The significant accounting policies followed in the preparation of these unaudited interim condensed consolidated financial statements are identical to those applied in the preparation of the latest annual financial statements. c. Critical accounting estimates: ASC 350 requires goodwill to be tested for impairment at the reporting unit level at least annually, or between annual tests under certain circumstances, and written down when impaired. Goodwill is tested for impairment by comparing the fair value of the reporting unit with it carrying value. Impairment charge of $ 671 as the carrying value of SaaS Solution reporting segment exceeded its expected fair value, as determined using a discounted cash flow model which is primarily based on management's future revenue and cost estimates. This impairment charge was recorded within Impairment of Goodwill, within the Consolidated Statement of Operations, and within the SaaS Solution segment for the year ended December 31, 2023. During the first quarter of 2024, there was no more likely than not indication of impairment, therefore no further impairment testing was required. d. Recent adopted accounting pronouncements: In June 2022, the FASB issued ASC 2022-03 "Fair Value Measurement of Equity Securities Subject to Contractual Sale Restrictions". The ASU clarifies that a contractual restriction on the sale of an equity security is not considered part of the unit of account of the equity security and, therefore, is not considered in measuring its fair value. The ASU also clarifies that an entity cannot, as a separate unit of account, recognize and measure a contractual sale restriction. The ASU also introduces new disclosure requirements for equity securities subject to contractual sale restrictions. The ASU do not have a material impact on the Company consolidated financial statements.